
Excellence through Research and Development of Innovative Biotechnology
HA TECH is an Australian based Company, Developing & Delivering innovative Diagnostic and Pharmaceuticals products, focuses on the diagnosis of serious infectious diseases: respiratory Including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. The Company is making long-term investments to develop pharmaceutical products and medical technologies/ devices to address major health problem in Australia and globally.
HA TECH Is Looking To Change The Industry Status Quo.
As members of the global healthcare community, HA TECH focuses on reducing the burden of disease with our products and development of novel technologies.
HA TECH aims to be inclusive and make diagnostic products that are accessible and only require basic laboratory equipment rather than restricting the use of kits to own brand equipment.
We value Science with our company run with an emphasis on researchers leading development.
HA Tech Board
Abdullah Mahmud
Executive ChairmanAbdullah boasts over 18 years of diverse work experience across Europe, Australia, and New Zealand. He holds a Bachelor of Engineering with Honors from the University of Greenwich, UK, supplemented by postgraduate studies at the University of Surrey, UK, and executive business courses from City University London.
Abdullah is the founder and Executive Chairman of HA Tech, a dynamic Sydney-based company founded in 2017, dedicated to the research and manufacturing of innovative diagnostics and biotechnology products. Under his leadership, HA Tech has experienced exceptional growth over the past five years, boasting over 30 commercialized diagnostic products in its pipeline.
Since its inception, HA Tech has made remarkable strides in the global market, successfully exporting TGA-approved products to more than 25 countries. The company proudly holds the largest diagnostic manufacturing capacity in Australia, with the capability to produce an impressive 10 million antigen tests and 40 million RT-PCR tests each month.
During the pandemic, HA Tech played a crucial role in the global response, exporting millions of COVID-19 test kits to Europe and Asia. This commitment to excellence in healthcare innovation earned the company the esteemed title of the 2022 Premier’s NSW Export Award winner.
Looking ahead, HA Tech is poised for an exciting future. The company is diligently establishing a multi-use biotechnology product facility with the ambitious goal of becoming the premier Australian provider of locally manufactured human insulin products on the international stage. Abdullah's vision and dedication continue to drive HA Tech's mission to revolutionize the biotechnology landscape, ensuring a healthier future for communities worldwide.
Dr. Hani Nur
Managing DirectorHani Nur, A Biotech Industry Expert, joined HA TECH in 2019 as Managing Director. Dr Nur has extensive experience in developing and commercializing a wide range of healthcare products & technologies, in particular: IVD Medical Devices (In-Vitro Diagnostics)
and Fertility Medical Devices for Assisted Reproductive Technology (ART) such as In Vitro Fertilisation (IVF). In addition to corporate, portfolio & growth strategy, she has significant working experience under a range of regulatory environments across ISO 9001 & 13485, and experience with QMS development / maintenance in product/process development, validation, manufacturing, Quality Assurance and Regulatory Affairs. Prior to joining HA TECH, Dr Nur worked as a Lead Scientist at the bio-separation company NuSep (currently Memphasys) at Sydney, Australia. At NuSep, she led multiple projects with team of varying sizes for several innovative bio-separation applications and patented the novel findings which include: long-life Polyacrylamide electrophoresis Gels for the separation of Proteins and DNA, Hydrogel Membranes for a Human Plasma Fractionation device to isolate high value proteins such as Albumin and Immunoglobulin (IgG) for therapeutic applications and Biocompatible Membranes for human ART Medical Devices to isolate healthy sperm cells for fertility treatments such as IVF.
Professor Martin Snowden
PhD, CSci, CChem, FRSC, PFHEA (UK)Prof. Martin Snowden is Pro Vice-chancellor and head of the Faculty of Engineering and Science at the University of Greenwich in London, UK. He has a distinguished track record of high-quality published output including the publication of
17 Q1 Pharmaceutical Science papers since 2014 (h-index 41). Professor Snowden is a Principal Fellow of the Higher Education Academy and an Eminent Fellow of the Academy of Pharmaceutical Sciences. He provides strategic leadership for all the International work of the University including its very successful Trans National Education provision. He also provides leadership and strategic development to 4 major academic disciplines including Engineering, Pharmacy, Science and the Natural Resources Institute. Professor Snowden has many successful partnerships with leading Pharmaceutical companies including Pfizer and GSK
Professor Fariba Dehghani
PhD (University of New South Wales, Australia)Professor Fariba Dehghani is currently the director of Centre for Advanced Food Engineering and a former director of an ARC Food Processing Training Centre at the University of Sydney, Australia. She was recognised by Engineers Australia as one of the Australian’s
top 50 Engineers for innovation. Her research team collaborated with industry to provide pragmatic, cost-effective and environmentally sustainable solutions to a diverse range of issues, with the aim of improving human wellbeing. After completion of her PhD degree at UNSW, she received the prestigious Australian Research Council Postdoctoral fellowship and continued working at UNSW as a senior research fellow and senior lecturer. She played a major role in the establishment of a R&D Company with Good Manufacturing Practice (GMP) facility and developed technologies and products that were sub-licensed to industries. Since joining the University of Sydney in 2006, she established a state-of-the-art bioengineering laboratory enabling multidisciplinary research collaboration. She promotes entrepreneurial engagement, resulting in four start-up companies being established by her research members. The focus of her current research is on developing biomaterials for medical devices, biosensors and nutraceuticals and food for promoting human health and environmental sustainability.
Dr Peter Valtchev
PhD (University of Sydney, Australia)Dr. Valtchev works in the department of Chemical and Biomolecular Engineering at the University of Sydney and has extensive experience in the fields of drug discovery and drug development, drug delivery, tissue engineering, therapeutic drug monitoring, metabolism and pharmacokinetics
He has more than 50 publications, 4 patents and his H-index is 18 reflecting work on multi-disciplinary projects involving therapeutic proteins, natural bioactive compounds, tissue scaffolds and drug delivery devices. Peter has more than 10 years of experience in the pharmaceutical and clinical diagnostics industry.
Prof. Shariff Enamul Kabir
PhD (University College London, UK)Prof. Kabir has been actively involved in research for the last 37 years in diverse field of chemistry. His research findings have shown direct applications in developing models of more complex polynuclear metal sites present in
heterogeneous catalytic systems. His innovative research that he has pioneered is utilized by industries to remove sulfur from organosulfur compounds present in petroleum-based feedstock which is crucial both environmentally and commercially. More recently, Prof. Kabir, in collaboration with Khan’s group of Bangladesh Atomic Energy Commission, has focused his attention towards developing natural and synthetic polymer blend composites. These elegant studies proved that the eco-friendly bio-degradable packaging material based on natural and synthetic polymers may be a good replacement of conventional synthetic packaging material. Prof. Kabir has built an active research group in organometallic cluster chemistry and bioinorganic chemistry in the department of chemistry at Jahangirnagar University. So far twenty-five Ph. D. and three M. Phil. students successfully obtained respective degrees under his supervision. Currently, fifteen M. Sc., M. Phil. and Ph. D. students are working on the various aspects of cluster chemistry and bioinorganic chemistry. Prof. Kabir presently holds and has held many strong administrative positions: Member Bangladesh Public Service Commission (2012- 2017); Vice-Chancellor (2009-2012), Treasurer (1998-2001), Chairman (2007-2009), Senate member (1998-present), and Syndicate member (2015-present) at Jahangirnagar University, Dhaka, Bangladesh He has maintained academic appointment, positions and research collaboration with number of universities worldwide includes University College London, UK; California State University Northridge, USA; University of Montana, USA; Freiburg University, Germany and Lund University, Sweden. He has published 324 research papers in prestigious Journals and reviewer of reputed International and National Journals. He has also made distinct contributions in mentoring young colleagues and scientists by fostering diversity and developing research facilities. Many students trained in his laboratory are currently working in various research institutions, industries and universities within the country and abroad successfully